. Author manuscript; available in PMC: 2008 Jun 17.

Published in final edited form as: Eur J Cancer. 2007 Jan 22;43(5):947–954. doi: 10.1016/j.ejca.2006.12.003

Table 2. HPRT promoter: bisulphite DNA sequencing results.

Cells	Number of sequenced clones	6TG (μM/days)	C at CpG sites (=methylated CpG)	C at non-CpG site (=bisulphite failure)
Male lymphocytes	7	0	04/301 (1.3%)	6/616 (1.0%)
Female lymphocytes	6	0	168/258 (65.1%)	21/528 (4.0%)
T84	11	0	8/473 (1.7%)	15/968 (1.5%)
T84	12	1/28 d	24/516 (4.7%)^a	22/1056 (2.1%)^b
SW620	2	0	0/86 (<1.2%)	0/176 (<0.6%)
SW620	2	0.25/7 d	0/86 (<1.2%)	0/176 (<0.6%)
SW620	5	1/7 d	4/215 (1.9%)^c	1/440 (0.2%)

All significance tested by Fisher’s exact test, two sided (except where indicated), results as P-values.

Control versus 6TG, P = 0.0108.

NS.

Control and 0.25 6TG versus 1 6TG, P = 0.1323 (one sided p = 0.0941).